Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2024-09-05
Target enrollment:
Participant gender:
Summary
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will
be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute
lymphoblastic leukemia (ALL).